GLP-1 · PEPTIDE
What is Cagrilintide?
Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026
THE SHORT ANSWER
Cagrilintide is an investigational long-acting analog of amylin, a hormone released with insulin that signals fullness. It is injected once a week and is being studied for weight management, alone and combined with semaglutide.
Cagrilintide at a glance
- Type
- Peptide
- Also known as
- AM833
- Mechanism
- Long-acting amylin analog
- Status
- Phase 3
- Half-life
- ~7–8 days
- Route
- Subcutaneous
- Dosing range in the literature
- 0.25–2.4 mg weekly
- Onset
- 2–4 weeks for satiety
- Storage
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date
How Cagrilintide works
Amylin slows stomach emptying and acts on the brain to produce satiety. Cagrilintide is engineered to last about a week instead of minutes, and it works through a different pathway than GLP-1 drugs, which is why the two are being combined.
What Cagrilintide is studied for
- Weight management
- Satiety
Phase 2 data showed dose-dependent weight loss on cagrilintide alone. Most late-stage evidence is for the combination with semaglutide.
Being studied for something is not proof that it works. Results in individuals vary.
Cagrilintide dosing
Published protocols describe 0.25–2.4 mg weekly, once weekly, given subcutaneous. Onset is typically reported at 2–4 weeks for satiety.
These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.
Cagrilintide side effects and risks
- Nausea
- Vomiting
- Injection-site reactions
Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.
Is Cagrilintide FDA approved?
Investigational. In late-stage trials and not approved by the FDA.
Approval and trial status change. This page was last reviewed on October 1, 2026.
Cagrilintide at G1 Peptides
G1 Peptides does not currently supply Cagrilintide. A provider can discuss alternatives in a free consultation.
Cagrilintide questions
- What is Cagrilintide?
- Cagrilintide is an investigational long-acting analog of amylin, a hormone released with insulin that signals fullness. It is injected once a week and is being studied for weight management, alone and combined with semaglutide.
- What is Cagrilintide used for?
- Cagrilintide is studied for weight management and satiety. Phase 2 data showed dose-dependent weight loss on cagrilintide alone. Most late-stage evidence is for the combination with semaglutide.
- How does Cagrilintide work?
- Amylin slows stomach emptying and acts on the brain to produce satiety. Cagrilintide is engineered to last about a week instead of minutes, and it works through a different pathway than GLP-1 drugs, which is why the two are being combined.
- Is Cagrilintide FDA approved?
- Investigational. In late-stage trials and not approved by the FDA.
- What is the typical Cagrilintide dosage?
- Published protocols describe 0.25–2.4 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
- What are the side effects of Cagrilintide?
- Risks noted for Cagrilintide include nausea, vomiting, and injection-site reactions. Tell your provider about your medications and conditions before starting.
- What is the half-life of Cagrilintide?
- The reported half-life is ~7–8 days. Onset is typically reported at 2–4 weeks for satiety.
- How should Cagrilintide be stored?
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date.
For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.